Literature DB >> 1512256

Functional characterization of protease-treated Bacillus anthracis protective antigen.

J M Novak1, M P Stein, S F Little, S H Leppla, A M Friedlander.   

Abstract

Characterization of the functional domains of Bacillus anthracis protective antigen (PA, 83-kDa), the common cellular binding molecule for both anthrax edema toxin and anthrax lethal toxin, is important for understanding the mechanism of entry and action of the anthrax toxins. In this study, we generated both biologically active (facilitates killing of J774A.1 cells in combination with lethal factor, LF) and inactive preparations of PA by protease treatment. Limited proteolytic digestion of PA in vitro with trypsin generated a 20-kDa fragment and a biologically active 63-kDa fragment. In contrast, limited digestion of PA with chymotrypsin yielded a preparation containing 37- and 47-kDa fragments defective for biological activity. Treatment with both chymotrypsin and trypsin generated three major fragments, 20, "17," and 47 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This PA preparation was also biologically inactive. To investigate the nature of the defect resulting from chymotrypsin treatment, we assayed PA preparations for the ability to bind to the cellular receptor and to bind and internalize 125I-LF. All radiolabeled PA preparations bound with specificity to J774A.1 cells and exhibited affinities similar to native 83-kDa PA. Once bound to the cell surface receptor, both trypsin-treated PA and chymotrypsin/trypsin-treated PA specifically bound 125I-LF with high affinity. Finally, these PA preparations delivered 125I-LF to a Pronase-resistant cellular compartment in a time- and temperature-dependent fashion. Thus, the biological defect exhibited by chymotrypsin-treated PA is not at the level of cell binding or internalization but at a step later, such as toxin routing or processing by J774A.1 cells. These protease-treated preparations of PA should prove useful in both elucidating the intracellular processing of anthrax lethal toxin and determining the structure-function relationship of PA and LF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512256

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design.

Authors:  Vladimir A Karginov; Ekaterina M Nestorovich; Mahtab Moayeri; Stephen H Leppla; Sergey M Bezrukov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-07       Impact factor: 11.205

Review 3.  Death at Sverdlovsk: what have we learned?

Authors:  D H Walker; O Yampolska; L M Grinberg
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

4.  Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.

Authors:  N Arora; S H Leppla
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

5.  Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.

Authors:  Y Singh; K R Klimpel; S Goel; P K Swain; S H Leppla
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

6.  Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Authors:  Andrei Soliakov; Ian F Kelly; Jeremy H Lakey; Allan Watkinson
Journal:  Eur J Pharm Biopharm       Date:  2011-09-22       Impact factor: 5.571

7.  Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.

Authors:  N M Cirino; D Sblattero; D Allen; S R Peterson; J D Marks; P J Jackson; A Bradbury; B E Lehnert
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

8.  The protective antigen component of anthrax toxin forms functional octameric complexes.

Authors:  Alexander F Kintzer; Katie L Thoren; Harry J Sterling; Ken C Dong; Geoffrey K Feld; Iok I Tang; Teri T Zhang; Evan R Williams; James M Berger; Bryan A Krantz
Journal:  J Mol Biol       Date:  2009-07-20       Impact factor: 5.469

Review 9.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

10.  Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Kemp B Cease
Journal:  Clin Vaccine Immunol       Date:  2013-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.